Ulcerative tuberculin skin test in a dialysis patient
Sir, A 53-year-old lady, hypertensive since 2003, was diagnosed with end-stage renal disease (ESRD) in January 2006 and initiated on continuous ambulatory peritoneal dialysis (CAPD). She has been on three exchanges per day with 2.5% dextrose solution. She used to achieve 1.5 L of ultrafiltration per day. Prior to this presentation, she had never suffered any mechanical or metabolic complications. Her peritoneal equilibration test revealed her to be a high average transporter. She presented with complaints of breathlessness, cough with no expectoration and anorexia. She had no peripheral oedema and fever. Her blood pressure was under control and echocardiography was normal. A chest radiograph revealed distention of pulmonary veins. Suspecting congestive heart failure, she was initiated on continuous cyclic peritoneal dialysis. There was an improvement in the breathlessness and cough, but her anorexia and fatigue had worsened. A tuberculin skin test (TST), was done with 5TU which ulcerated within 24 h, suggesting an infection due to Mycobacterium tuberculosis ( Figure 1 ). She improved within a week of initiation of isoniazid (5 mg/kg), rifampin (15 mg/kg) and pyrazinamide (10 mg/kg), aimed at treating latent tuberculosis. A retrospective search for tuberculous infection was negative. She had a scar of BCG vaccination on her deltoid, administered in her infancy. False negative reactions to TST are reported in HIV infection, severe tuberculous disease, chronic renal failure, diabetes mellitus, old age and newborn infants. The prevalence of anergy to TST was significantly higher in the ESRD population (44% vs 16%, P < 0.001) [1] . An ulcerative TST reaction is indirect evidence of an active tuberculous lesion in the body, even if it is not manifest. An induration >10 mm is considered positive in persons with a medical condition that increases the risk of tuberculosis, which includes ESRD patients [2] . Three regimes, isoniazid only, rifampin only, or rifampin plus pyrazinamide, are recommended for the treatment of latent tuberculosis. We used a three-drug regime as this is the practice at our institute. Two consecutive TSTs combined with a chest radiograph should be performed at the start of dialysis, to detect those patients with latent Mycobacterium tuberculosis infection [3] . [2] . Outcomes of kidney transplantation are poor, due to recurrent allograft disease or progression of the underlying plasma cell dyscrasia [1, 3] . Thus, renal transplant strategies must address the underlying disease. We describe the first reported case of LCDD treated with sequential autologous peripheral blood stem cell (PBSC) transplantation and kidney transplantation.
A 58-year-old male presented with mild anaemia and renal impairment (serum creatinine 2.8 mg/dl). Urinary protein excretion was 0.71 g/day. Serum protein electrophoresis revealed an IgG kappa paraprotein level of 1000 mg/dl, with depressed IgA and IgM. Bone marrow examination showed 5-6% plasma cells. Renal biopsy showed granular tubular protein deposits, thickening of the tubular basement membrane and peri-tubular sclerosis, in keeping with LCDD. Kappa light chain immunoperoxidase stain was positive (Figure 1) . The patient was treated with chemotherapy, Twenty-six months post-renal transplant, IgG level was 500 mg/dl, with serum kappa free light chains of 72.3 mg/l. MRI and sestamibi scans showed active disease in the left femur and right iliac crest. Bone marrow biopsy showed 4% plasma cells, although with considerably more noted on CD138 staining. Thalidomide and dexamethasone were commenced, with a plan for a further autologous PBSC transplant with higher dose melphalan. Renal function was stable at 1.7 mg/dl. A kidney biopsy at this stage showed no recurrence of light chain deposition.
Our patient is the first case of LCDD treated with sequential transplantation. Leung et al. [4] described seven patients with the related disorder primary amyloidosis who underwent sequential kidney transplantation and autologous PBSC transplantation. Kidney transplantation was performed first because of the limitations on drug dosing imposed by ESRF. One patient died, but the rest remained well without recurrent amyloidosis (follow-up period 0.7-4.1 years).
Our decision to perform PBSC transplantation first was based on concerns about additive risks of chemotherapy and post-renal transplant immunosuppression. Chemotherapy dose was modified because of renal impairment. There was still significant treatment-related toxicity with incomplete suppression and subsequent progression of the underlying disease, despite no evidence of recurrent light chain deposition in the renal allograft.
Human Urotensin II in the plasma of anephric subjects Sir, Human urotensin II (UII), perhaps the most potent mammalian vasoconstrictor known, is thought to be produced by the kidneys. The urotensins are a family of vasoactive peptides first isolated from various fish species over 20 years ago. Homologous peptides have been isolated in numerous species including frogs, rodents, pigs, primates and humans. It has been demonstrated in-vitro that human UII is between 8-and 110-fold more potent than endothelin-1 as a vasoconstrictor, and is the most potent mammalian vasoconstrictor known. The precise metabolic pathway(s) of urotensin metabolism is unknown, though high density of UII and its receptor have been demonstrated in mouse and monkey kidneys [1] and human kidneys, [2] and is thus thought to be synthesized, secreted and cleared by the kidneys [3, 4, 5] . Also, some researchers have reported higher blood values of UII in patients with kidney disease as well as with hypertension. These reports have stimulated interest in a possible aetiological role of UII in kidney disease and hypertension in people with kidney disease; consequently we sought to determine whether plasma concentrations of UII are detectable in subjects with end-stage renal disease (ESRD) on dialysis, and in particular in surgically anephric subjects.
Thirty-one ESRD subjects undergoing routine haemodialysis were enrolled, including two surgically anephric subjects (i.e. both patients had bilateral nephrectomy at least 6 months prior to enrolment). Blood samples were obtained for UII before initiation of a mid-week dialysis session. UII concentrations were measured in unextracted plasma by radioimmunoassay using human UII-specific monoclonal antibody at GlaxoSmithKline laboratories (NA). The mean UII was compared between anephric and non-anephric subjects with a paired Students' t-test, using JMP IN statistical software version 4 (SAS Institute, Carey, NC, USA). 
